High-level expression and one-step purification of recombinant dengue virus type 2 envelope domain III protein in Escherichia coli

Protein Expression and Purification

Volumn 33, Issue 1, 2004, Pages 80-91

  Jaiswal, Smita ^a   Khanna, Navin ^a   Swaminathan, Sathyamangalam ^a  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY ICGEB   (India)

Author keywords

3H5 monoclonal antibody; 6x His Tag; Dengue virus type 2; Domain III; Envelope protein; Ni NTA chromatography

Indexed keywords

DENGUE VIRUS; DENGUE VIRUS TYPE 2; ESCHERICHIA COLI; MURINAE;

EID: 0346966132     PISSN: 10465928     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pep.2003.09.009     Document Type: Article

References (41)

1. D.J. Gubler, Dengue and dengue haemorrhagic fever, Clin. Microbiol. Rev. 11 (1998) 480-496.
2. P. Leyssen, E. De Clercq, J. Neyts, Perspectives for the treatment and infections with Flaviviridae, Clin. Microb. Rev. 13 (2000) 67-82.
3. N. Bhamarapravati, Y. Sutee, Live attenuated tetravalent dengue vaccine, Vaccine 18 (2000) 44-47.
4. C.J. Lai, M. Bray, R. Men, A. Cahour, W. Chen, H. Kawano, M. Tadano, K. Hiramatsu, I. Tokimatsu, A. Pletnev, S. Arakai, G. Shameem, M. Rinaudo, Evaluation of molecular strategies to develop a live dengue vaccine, Clin. Diagn. Virol. 10 (1998) 173-179.
5. F. Guirakhoo, J. Arroyo, K.V. Pugachev, C. Miller, Z.-X. Zhang, R. Weltzin, K. Georgakopoulos, J. Catalan, S. Ocran, K. Soike, M. Ratterree, T.P. Monath, Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine, J. Virol. 75 (2001) 7290-7304.
6. R. Putnak, D.A. Barvir, J.M. Burrous, D.R. Dubois, V.M. Dandrea, C.H. Hoke, J.C. Sadoff, K.H. Eckels, Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys, J. Infect. Dis. 174 (1996) 1176-1184.
7. B.A.L. Fonseca, S. Pincus, R.E. Shope, E. Paoletti, P.W. Mason, Recombinant vaccinia viruses co-expressing dengue-1 glycoproteins prM and E induce neutralizing antibodies in mice, Vaccine 12 (1994) 279-285.
8. R. Men, L. Wyatt, I. Tokimatsu, S. Arakaki, G. Shameem, R. Elkins, R. Chanock, B. Moss, C.-J. Lai, Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge, Vaccine 18 (2000) 3113-3122.
9. T.J. Kochel, K. Raviprakash, C.G. Hayes, D.M. Watts, K.L. Russell, A.S. Gozalo, I.A. Phillips, D.F. Ewing, G.S. Murphy, K.R. Porter, A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys, Vaccine 18 (2000) 3166-3173.
10. E. Konishi, M. Yamaoka, I. Kurane, P.W. Mason, A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice, Vaccine 18 (2000) 1133-1139.
11. A.K. Srivastava, J.R. Putnak, R.L. Warren, C.H. Hoke Jr., Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection, Vaccine 13 (1995) 1251-1258.
12. R.J. Sugrue, T. Cui, Q. Xu, J. Fu, Y.C. Chan, The production of recombinant dengue virus E protein using Escherichia coli and Pichia pastoris, J. Virol. Methods 69 (1997) 159-169.
13. M. Simmons, W.M. Nelson, S.J.L. Wu, C.G. Hayes, Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice, Am. J. Trop. Med. Hyg. 58 (1998) 655-662.
14. H. Bisht, D.A. Chugh, S. Swaminathan, N. Khanna, Expression and purification of dengue virus type 2 envelope protein as a fusion with Hepatitis B surface antigen in Pichia pastoris. Protein Exp. Purif. 23 (2001) 84-96.
15. L. Hermida, R. Rodríguez, L. Lazo, C. López, G. Márquez, R. Páez, C. Suárez, R. Espinosa, J. García, G. Guzmán, G. Guillén, A recombinant envelope protein from dengue virus purified by IMAC is bioequivalent with its immune-affinity chromatography purified counterpart, J. Biotechnol. 94 (2002) 213-216.
16. I. Staropoli, J.M. Clément, M.P. Frenkiel, M. Hofnung, V. Deubel, Dengue virus envelope glycoprotein can be secreted from insect cells as a fusion with the maltose-binding protein, J. Virol. Methods 56 (1996) 179-189.
17. I. Staropoli, M.-P. Frenkiel, F. Mégret, V. Deubel, Affinity-purified dengue-2 virus envelope glycoprotein induces neutralizing antibodies and protective immunity in mice, Vaccine 15 (1997) 1946-1954.
18. E.P. Kelly, J.J. Greene, A.D. King, B.L. Innis, Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice, Vaccine 18 (2000) 2549-2559.
19. B.D. Lindenbach, C.M. Rice, Flaviviridae: the viruses and their replication, in: D.M. Knipe, P.M. Howley (Eds.), Fields Virology, fourth ed., Lippincott Williams & Wilkins, Philadelphia, 2001, pp. 91-1041.
20. Y. Chen, T. Maguire, R.M. Marks, Demonstration of binding of dengue envelope protein to target cells, J. Virol. 70 (1996) 8765-8772.
21. R.J. Kuhn, W. Zhang, M.G. Rossman, S.V. Pletnev, J. Corver, E. Lenches, C.T. Jones, S. Mukhopadhyay, P.R. Chipman, E.G. Strauss, T.S. Baker, J.H. Strauss, Structure of dengue virus: implications for flavivirus organization, maturation, and fusion, Cell 108 (2002) 717-725.
22. F. Mégret, J.P. Hugnot, A. Falconar, M.K. Gentry, D.M. Morens, J.M. Murray, J.J. Schlesinger, P.J. Wright, P. Young, M.H.V. van Regenmortel, V. Deubel, Use of recombinant fusion proteins and monoclonal antibodies to define linear and discontinuous antigenic sites on the dengue envelope glycoprotein, Virology 187 (1992) 480-491.
23. W.D. Crill, J.T. Roehrig, Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells, J. Virol. 75 (2001) 7769-7773.
24. M. Simmons, G.S. Murphy, C.G. Hayes, Short report: antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine, Am. J. Trop. Med. Hyg. 65 (2001) 159-161.
25. U.K. Laemmli, Cleavage of structural proteins during the assembly of the head of bacteriophage T4, Nature 227 (1970) 680-685.
26. D. Arora, N. Khanna, Method for increasing the yield of properly folded recombinant human gamma interferon from inclusion bodies, J. Biotechnol. 52 (1996) 127-133.
27. S. Swaminathan, N. Khanna, Affinity purification of recombinant interferon-α on a mimetic ligand adsorbent, Protein Exp. Purif. 15 (1999) 236-242.
28. M.M. Bradford, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding, Anal. Biochem. 72 (1976) 248-254.
29. F.G. Burleson, T.M. Chambers, D.L. Wiedbrauk, Virology: A Laboratory Manual, Academic Press, New York, 1992.
30. S. Bhardwaj, M. Holbrook, R.E. Shope, A.D.T. Barrett, S.J. Watowich, Biophysical characterization and vector-specific antagonist activity of domain III of the tick-borne flavivirus envelope protein, J. Virol. 75 (2001) 4002-4007.
31. B.M. Kaufman, P.L. Summers, D.R. Dubois, K.H. Eckels, Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection, Am. J. Trop. Med. Hyg. 36 (1987) 427-434.
32. V. Churdboonchart, N. Bhamarapravati, S. Peampramprecha, S. Srinavin, Antibodies against dengue viral proteins in primary and secondary dengue hemorrhagic fever, Am. J. Trop. Med. Hyg. 44 (1991) 481-493.
33. R. Feighny, J. Burrous, J. McCown, C. Hoke, R. Putnak, Purification of native dengue-2 viral proteins and the ability of purified proteins to protect mice, Am. J. Trop. Med. Hyg. 47 (1992) 405-412.
34. D.V. Goeddel, Systems for heterologous gene expression, Methods Enzymol. 185 (1990) 3-7.
35. Y. Modis, S. Ogata, D. Clements, S.C. Harrison, A ligand-binding pocket in the dengue virus envelope glycoprotein, Proc. Natl. Acad. Sci. USA 100 (2003) 6986-6991.
36. F.A. Rey, F.X. Heinz, C. Mandl, C. Kunz, S.C. Harrison, The envelope glycoprotein from tick-borne encephalitis virus at 2 Å resolution, Nature 375 (1995) 291-298.
37. P. Thullier, C. Demangel, H. Bedouelle, F. Mégret, A. Jouan, V. Deubel, J.-C. Mazié, P. Lafaye, Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism, J. Gen. Virol. 82 (2001) 1885-1892.
38. B.A.L. Fonseca, K. Khoshnood, R.E. Shope, P.W. Mason, Flavivirus type-specific antigens produced from fusions of a portion of the E protein gene with the E. coli trpE gene, Am. J. Trop. Med. Hyg. 44 (1991) 500-508.
39. T. Trirawatanapong, B. Chandran, R. Putnak, R. Padmanabhan, Mapping of a region of dengue virus type-2 glycoprotein required for binding by a neutralizing monoclonal antibody, Gene 116 (1992) 139-150.
40. F. Guirakhoo, R.A. Bolin, J.T. Roehrig, The Murray Valley Encephalitis virus prM protein confers acid resistance to virus particles and alters the expression of epitopes within the R2 domain of the E glycoprotein, Virology 191 (1992) 921-931.
41. J.T. Roehrig, J.J. Johnson, A.R. Hunt, R.A. Bolin, M.C. Chu, Antibodies to dengue 2 virus E-glycoprotein synthetic peptides identify antigenic conformation, Virology 177 (1990) 668-765.